Cargando…
Novel covalent CDK7 inhibitor potently induces apoptosis in acute myeloid leukemia and synergizes with Venetoclax
INTRODUCTION: The emergence of resistance to the highly successful BCL2-directed therapy is a major unmet need in acute myeloid leukemia (AML), an aggressive malignancy with poor survival rates. Towards identifying therapeutic options for AML patients who progress on BCL2-directed therapy, we studie...
Autores principales: | , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10386772/ https://www.ncbi.nlm.nih.gov/pubmed/37507802 http://dx.doi.org/10.1186/s13046-023-02750-w |
_version_ | 1785081750231187456 |
---|---|
author | Gaur, Tarang Poddutoori, Ramulu Khare, Leena Bagal, Bhausaheb Rashmi, Sonal Patkar, Nikhil Tembhare, Prashant PG, Subramanian Shetty, Dhanlaxmi Dutt, Amit Zhang, Qi Konopleva, Marina Platzbeckar, Uwe Gupta, Sudeep Samajdar, Susanta Ramchandra, Murali Khattry, Navin Hasan, Syed K. |
author_facet | Gaur, Tarang Poddutoori, Ramulu Khare, Leena Bagal, Bhausaheb Rashmi, Sonal Patkar, Nikhil Tembhare, Prashant PG, Subramanian Shetty, Dhanlaxmi Dutt, Amit Zhang, Qi Konopleva, Marina Platzbeckar, Uwe Gupta, Sudeep Samajdar, Susanta Ramchandra, Murali Khattry, Navin Hasan, Syed K. |
author_sort | Gaur, Tarang |
collection | PubMed |
description | INTRODUCTION: The emergence of resistance to the highly successful BCL2-directed therapy is a major unmet need in acute myeloid leukemia (AML), an aggressive malignancy with poor survival rates. Towards identifying therapeutic options for AML patients who progress on BCL2-directed therapy, we studied a clinical-stage CDK7 inhibitor XL102, which is being evaluated in solid tumors (NCT04726332). MATERIALS AND METHODS: To determine the anti-proliferative effects of XL102, we performed experiments including time-resolved fluorescence resonance energy transfer, target occupancy, cell cycle and apoptosis-based assays. We also included genetically characterized primary myeloid blasts from de novo and relapsed/refractory AML patients. For mechanistic studies, CRISPR/Cas9 mediated knockout of CDK7 and c-Myc and immunoblotting were performed. NOD/SCID orthotropic and subcutaneous AML xenografts were used to determine anti-leukemic effects. To assess the synergistic effects of XL102 with Venetoclax, we performed RNA sequencing and gene set enrichment analysis using Venetoclax sensitive and resistant model systems. RESULTS: XL102, a highly specific, orally bioavailable covalent inhibitor of CDK7. Inhibitory effect on CDK7 by XL102 in primary myeloid blasts (n = 54) was in nanomolar range (mean = 300 nM; range = 4.0-952 nM). XL102 treated AML cells showed a reduction in phosphorylation levels of Serine 2/5/7 at carboxy-terminal domain of RNA polymerase II. T-loop phosphorylation of CDK1(Thr161) and CDK2(Thr160) was inhibited by XL102 in dose-dependent manner leading to cell-cycle arrest. c-Myc downregulation and enhanced levels of p53 and p21 in XL102 treated cells were observed. Increased levels of p21 and activation of p53 by XL102 were mimicked by genetic ablation of CDK7, which supports that the observed effects of XL102 are due to CDK7 inhibition. XL102 treated AML xenografts showed remarkable reduction in hCD45 + marrow cells (mean = 0.60%; range = 0.04%-3.53%) compared to vehicle control (mean = 38.2%; range = 10.1%-78%), with corresponding increase in p53, p21 and decrease in c-Myc levels. The data suggests XL102 induces apoptosis in AML cells via CDK7/c-Myc/p53 axis. RNA-sequencing from paired Venetoclax-sensitive and Venetoclax-resistant cells treated with XL102 showed downregulation of genes involved in proliferation and apoptosis. CONCLUSION: Taken together, XL102 with Venetoclax led to synergistic effects in overcoming resistance and provided a strong rationale for clinical evaluation of XL102 as a single agent and in combination with Venetoclax. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13046-023-02750-w. |
format | Online Article Text |
id | pubmed-10386772 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-103867722023-07-30 Novel covalent CDK7 inhibitor potently induces apoptosis in acute myeloid leukemia and synergizes with Venetoclax Gaur, Tarang Poddutoori, Ramulu Khare, Leena Bagal, Bhausaheb Rashmi, Sonal Patkar, Nikhil Tembhare, Prashant PG, Subramanian Shetty, Dhanlaxmi Dutt, Amit Zhang, Qi Konopleva, Marina Platzbeckar, Uwe Gupta, Sudeep Samajdar, Susanta Ramchandra, Murali Khattry, Navin Hasan, Syed K. J Exp Clin Cancer Res Research INTRODUCTION: The emergence of resistance to the highly successful BCL2-directed therapy is a major unmet need in acute myeloid leukemia (AML), an aggressive malignancy with poor survival rates. Towards identifying therapeutic options for AML patients who progress on BCL2-directed therapy, we studied a clinical-stage CDK7 inhibitor XL102, which is being evaluated in solid tumors (NCT04726332). MATERIALS AND METHODS: To determine the anti-proliferative effects of XL102, we performed experiments including time-resolved fluorescence resonance energy transfer, target occupancy, cell cycle and apoptosis-based assays. We also included genetically characterized primary myeloid blasts from de novo and relapsed/refractory AML patients. For mechanistic studies, CRISPR/Cas9 mediated knockout of CDK7 and c-Myc and immunoblotting were performed. NOD/SCID orthotropic and subcutaneous AML xenografts were used to determine anti-leukemic effects. To assess the synergistic effects of XL102 with Venetoclax, we performed RNA sequencing and gene set enrichment analysis using Venetoclax sensitive and resistant model systems. RESULTS: XL102, a highly specific, orally bioavailable covalent inhibitor of CDK7. Inhibitory effect on CDK7 by XL102 in primary myeloid blasts (n = 54) was in nanomolar range (mean = 300 nM; range = 4.0-952 nM). XL102 treated AML cells showed a reduction in phosphorylation levels of Serine 2/5/7 at carboxy-terminal domain of RNA polymerase II. T-loop phosphorylation of CDK1(Thr161) and CDK2(Thr160) was inhibited by XL102 in dose-dependent manner leading to cell-cycle arrest. c-Myc downregulation and enhanced levels of p53 and p21 in XL102 treated cells were observed. Increased levels of p21 and activation of p53 by XL102 were mimicked by genetic ablation of CDK7, which supports that the observed effects of XL102 are due to CDK7 inhibition. XL102 treated AML xenografts showed remarkable reduction in hCD45 + marrow cells (mean = 0.60%; range = 0.04%-3.53%) compared to vehicle control (mean = 38.2%; range = 10.1%-78%), with corresponding increase in p53, p21 and decrease in c-Myc levels. The data suggests XL102 induces apoptosis in AML cells via CDK7/c-Myc/p53 axis. RNA-sequencing from paired Venetoclax-sensitive and Venetoclax-resistant cells treated with XL102 showed downregulation of genes involved in proliferation and apoptosis. CONCLUSION: Taken together, XL102 with Venetoclax led to synergistic effects in overcoming resistance and provided a strong rationale for clinical evaluation of XL102 as a single agent and in combination with Venetoclax. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13046-023-02750-w. BioMed Central 2023-07-29 /pmc/articles/PMC10386772/ /pubmed/37507802 http://dx.doi.org/10.1186/s13046-023-02750-w Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Gaur, Tarang Poddutoori, Ramulu Khare, Leena Bagal, Bhausaheb Rashmi, Sonal Patkar, Nikhil Tembhare, Prashant PG, Subramanian Shetty, Dhanlaxmi Dutt, Amit Zhang, Qi Konopleva, Marina Platzbeckar, Uwe Gupta, Sudeep Samajdar, Susanta Ramchandra, Murali Khattry, Navin Hasan, Syed K. Novel covalent CDK7 inhibitor potently induces apoptosis in acute myeloid leukemia and synergizes with Venetoclax |
title | Novel covalent CDK7 inhibitor potently induces apoptosis in acute myeloid leukemia and synergizes with Venetoclax |
title_full | Novel covalent CDK7 inhibitor potently induces apoptosis in acute myeloid leukemia and synergizes with Venetoclax |
title_fullStr | Novel covalent CDK7 inhibitor potently induces apoptosis in acute myeloid leukemia and synergizes with Venetoclax |
title_full_unstemmed | Novel covalent CDK7 inhibitor potently induces apoptosis in acute myeloid leukemia and synergizes with Venetoclax |
title_short | Novel covalent CDK7 inhibitor potently induces apoptosis in acute myeloid leukemia and synergizes with Venetoclax |
title_sort | novel covalent cdk7 inhibitor potently induces apoptosis in acute myeloid leukemia and synergizes with venetoclax |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10386772/ https://www.ncbi.nlm.nih.gov/pubmed/37507802 http://dx.doi.org/10.1186/s13046-023-02750-w |
work_keys_str_mv | AT gaurtarang novelcovalentcdk7inhibitorpotentlyinducesapoptosisinacutemyeloidleukemiaandsynergizeswithvenetoclax AT poddutooriramulu novelcovalentcdk7inhibitorpotentlyinducesapoptosisinacutemyeloidleukemiaandsynergizeswithvenetoclax AT khareleena novelcovalentcdk7inhibitorpotentlyinducesapoptosisinacutemyeloidleukemiaandsynergizeswithvenetoclax AT bagalbhausaheb novelcovalentcdk7inhibitorpotentlyinducesapoptosisinacutemyeloidleukemiaandsynergizeswithvenetoclax AT rashmisonal novelcovalentcdk7inhibitorpotentlyinducesapoptosisinacutemyeloidleukemiaandsynergizeswithvenetoclax AT patkarnikhil novelcovalentcdk7inhibitorpotentlyinducesapoptosisinacutemyeloidleukemiaandsynergizeswithvenetoclax AT tembhareprashant novelcovalentcdk7inhibitorpotentlyinducesapoptosisinacutemyeloidleukemiaandsynergizeswithvenetoclax AT pgsubramanian novelcovalentcdk7inhibitorpotentlyinducesapoptosisinacutemyeloidleukemiaandsynergizeswithvenetoclax AT shettydhanlaxmi novelcovalentcdk7inhibitorpotentlyinducesapoptosisinacutemyeloidleukemiaandsynergizeswithvenetoclax AT duttamit novelcovalentcdk7inhibitorpotentlyinducesapoptosisinacutemyeloidleukemiaandsynergizeswithvenetoclax AT zhangqi novelcovalentcdk7inhibitorpotentlyinducesapoptosisinacutemyeloidleukemiaandsynergizeswithvenetoclax AT konoplevamarina novelcovalentcdk7inhibitorpotentlyinducesapoptosisinacutemyeloidleukemiaandsynergizeswithvenetoclax AT platzbeckaruwe novelcovalentcdk7inhibitorpotentlyinducesapoptosisinacutemyeloidleukemiaandsynergizeswithvenetoclax AT guptasudeep novelcovalentcdk7inhibitorpotentlyinducesapoptosisinacutemyeloidleukemiaandsynergizeswithvenetoclax AT samajdarsusanta novelcovalentcdk7inhibitorpotentlyinducesapoptosisinacutemyeloidleukemiaandsynergizeswithvenetoclax AT ramchandramurali novelcovalentcdk7inhibitorpotentlyinducesapoptosisinacutemyeloidleukemiaandsynergizeswithvenetoclax AT khattrynavin novelcovalentcdk7inhibitorpotentlyinducesapoptosisinacutemyeloidleukemiaandsynergizeswithvenetoclax AT hasansyedk novelcovalentcdk7inhibitorpotentlyinducesapoptosisinacutemyeloidleukemiaandsynergizeswithvenetoclax |